Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease

被引：204

作者：

Rosenson, Robert S. ^{[1
]}

Davidson, Michael H. ^{[2
]}

Hirsh, Benjamin J. ^{[3
]}

Kathiresan, Sekar ^{[4
]}

Gaudet, Daniel ^{[5
,6
]}

机构：

[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[2] Univ Chicago, Pritzker Sch Med, Div Cardiol, Chicago, IL 60637 USA

[3] Mt Sinai Hosp, New York, NY 10029 USA

[4] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA

[5] Univ Montreal, Dept Med, ECOGENE 21, Chicoutimi, PQ, Canada

[6] Univ Montreal, Dept Med, Lipid Clin, Chicoutimi, PQ, Canada

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2014年 / 64卷 / 23期

关键词：

atherosclerosis; cardiovascular disease; genetics; triglyceride; triglyceride-rich lipoproteins; LOW-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; APOLIPOPROTEIN C-III; ALIPOGENE TIPARVOVEC AAV1-LPLS447X; TISSUE-SPECIFIC EXPRESSION; CYTOSOLIC LIPID DROPLETS; GENOME-WIDE ASSOCIATION; EXTENDED-RELEASE NIACIN; NONFASTING TRIGLYCERIDES; SEVERE HYPERTRIGLYCERIDEMIA;

D O I：

10.1016/j.jacc.2014.09.042

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Triglycerides represent 1 component of a heterogeneous pool of triglyceride-rich lipoproteins (TGRLs). The reliance on triglycerides or TGRLs as cardiovascular disease (CVD) risk biomarkers prompted investigations into therapies that lower plasma triglycerides as a means to reduce CVD events. Genetic studies identified TGRL components and pathways involved in their synthesis and metabolism. We advocate that only a subset of genetic mechanisms regulating TGRLs contribute to the risk of CVD events. This " omic" approach recently resulted in new targets for reducing CVD events. (C) 2014 by the American College of Cardiology Foundation.

引用

页码：2525 / 2540

页数：16

共 50 条

[1] GENETICS OF TRIGLYCERIDE-RICH LIPOPROTEINS AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
Rosenson, R. S.
CARDIOLOGY, 2015, 131 : 245 - 245
[2] Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease Risk
Duell, P. Barton
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (02) : 153 - 155
[3] Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk
Vishwesh M. Bharadiya
Swasti Rawal
Vardhmaan Jain
Parag A. Chevli
Anurag Mehta
Current Cardiovascular Risk Reports, 2022, 16 : 131 - 144
[4] An update on triglyceride-rich lipoproteins and their remnants in atherosclerotic cardiovascular disease
Crea, Filippo
EUROPEAN HEART JOURNAL, 2021, 42 (47) : 4777 - 4780
[5] Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk
Bharadiya, Vishwesh M.
Rawal, Swasti
Jain, Vardhmaan
Chevli, Parag A.
Mehta, Anurag
CURRENT CARDIOVASCULAR RISK REPORTS, 2022, 16 (11) : 131 - 144
[6] Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease New Insights From Epidemiology, Genetics, and Biology
Nordestgaard, Borge G.
CIRCULATION RESEARCH, 2016, 118 (04) : 547 - 563
[7] Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease
Ganda, Om P.
CURRENT OPINION IN LIPIDOLOGY, 2023, 34 (03) : 105 - 113
[8] Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease risk: current status and treatments
Reyes-Soffer, Gissette
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2021, 28 (02) : 85 - 89
[9] Small Remnants versus Large Triglyceride-Rich Lipoproteins in Risk of Atherosclerotic Cardiovascular Disease
Wadstrom, Benjamin N.
Wulff, Anders B.
Pedersen, Kasper M.
Nordestgaard, Borge G.
CLINICAL CHEMISTRY, 2025,
[10] Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease
Chait, Alan
Ginsberg, Henry N.
Vaisar, Tomas
Heinecke, Jay W.
Goldberg, Ira J.
Bornfeldt, Karin E.
DIABETES, 2020, 69 (04) : 508 - 516

← 1 2 3 4 5 →